US23284P1030 - Common Stock
CYTEIR THERAPEUTICS INC
NASDAQ:CYT (3/15/2024, 8:00:01 PM)
After market: 3.1 +0.08 (+2.65%)3.02
-0.07 (-2.27%)
Cyteir Therapeutics, Inc.is a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. The company is headquartered in Lexington, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2021-06-18. The firm is focused on developing of CYT-0851, an oral investigational drug candidate that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor (MCT) inhibitor, initially evaluated in a phase I/II study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard of care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy. Its CYT-0851 is also in development in combination with capecitabine and gemcitabine in a Phase I/II clinical study, including patients with advanced ovarian cancer.
CYTEIR THERAPEUTICS INC
99 Hayden Avenue, Building B, Suite 450
Lexington MASSACHUSETTS
P: 18572854140
CEO: Markus Renschler
Employees: 46
Website: https://cyteir.com/
A little-known biotech company, Cyteir Therapeutics Inc., is about to notch its best day ever — on the back of plans to dissolve the company.
Here you can normally see the latest stock twits on CYT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: